Saturday, October 31, 2026

New York Times Stock Is 14% Up At Session Start On Wednesday

ViaNews Editorial Team

February 8, 2023

New York Times Stock Is 14% Up At Session Start On Wednesday

(VIANEWS) - Shares of New York Times (NYSE: NYT) rose by a staggering 14.6% to $42.07 at 10:09 EST on Wednesday, after two consecutive sessions in a row of gains. NYSE is rising 0.79% to $16,021.62, following the last session's upward trend. This seems, at the moment, a somewhat positive trend trading session today.

New York Times's last close was $36.71, 22.99% under its 52-week high of $47.67.

About New York Times

The New York Times Company, together with its subsidiaries, provides news and information for readers and viewers across various platforms worldwide. It offers The New York Times (The Times), a daily and Sunday newspaper in the United States, as well as international edition of The Times; and operates the NYTimes.com Website. The company also transmits articles, graphics, and photographs from The Times and other publications to approximately 1,500 newspapers, magazines, and websites; licenses electronic databases to resellers in the business, professional, and library markets; and offers magazine licensing, news digests, book development, and rights and permissions. In addition, it engages in the live events business, which hosts physical and virtual live events to connect audiences with journalists and outside thought leaders; direct-sold website, mobile application, podcast, email, and video advertisements, as well as digital advertising services; operates Wirecutter, a product review and recommendation products; develops mobile applications, including games and cooking products; prints and distributes products for third parties; and offers other products and services. The company was founded in 1851 and is headquartered in New York, New York.

Earnings Per Share

As for profitability, New York Times has a trailing twelve months EPS of $0.6.

PE Ratio

New York Times has a trailing twelve months price to earnings ratio of 70.12. Meaning, the purchaser of the share is investing $70.12 for every dollar of annual earnings.

The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.91%.

Volatility

New York Times's last week, last month's, and last quarter's current intraday variation average was 1.46%, 0.53%, and 1.22%.

New York Times's highest amplitude of average volatility was 1.83% (last week), 1.13% (last month), and 1.22% (last quarter).

Revenue Growth

Year-on-year quarterly revenue growth grew by 11.6%, now sitting on 2.17B for the twelve trailing months.

Sales Growth

New York Times's sales growth is 9.9% for the ongoing quarter and 7.7% for the next.

Stock Price Classification

According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,

New York Times's stock is considered to be overbought (>=80).

More news about New York Times (NYT).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Data Wave Builds Toward Ivonescimab PDUFA, While Micro-Cap Biotech Exits the Market
Late October 2026 is a dense catalyst window led by ESMO 2026. Daiichi Sankyo's DXd antibody-drug conjugate (ADC) programs (DESTINY-Lung04, DESTINY-Breast11, REJOICE-Ovarian01/02, TUXEDO-3), Guardant's 25 abstracts and the PACE-LUNG ctDNA trial all report there. These feed into the FDA's 14 November 2026 PDUFA date for ivonescimab. Large and mid-cap developers with late-stage data and commercial launches (ZEGFROVY, ANKTIVA, MIUDELLA, lorundrostat, duvakitug) are drawing capital and attention. Spago Nanomedical's board decision to seek a Nasdaq First North delisting (EGM 19 November, application 25 January 2027) shows the capital squeeze on early-stage, single-asset names (Tumorad is Phase I).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,514 source documents archived
Query this data → isubstrate.com